As advised via PHARMAC Tender Results of 29 March 2019 there is to be a change in the listing and future sole supply of Temozolomide Capsules.

New listing from 1 December 2019

Temaccord Caps 5 mg 5 capsule bottle pack                                                        Pharmacode 2388278                                        Schedule price $9.13

Temaccord Caps 20 mg 5 capsule bottle pack                                                                  Pharmacode 2388251                                    Schedule price $16.38

Temaccord Caps 100 mg 5 capsule bottle pack                                                                Pharmacode 2388243                                    Schedule price $35.98

Temaccord Caps 140 mg 5 capsule bottle pack                                       Pharmacode TBA                                     Schedule price $50.12

Temaccord Caps 250 mg 5 capsule bottle pack                                       Pharmacode 2388235                                      Schedule price $86.34

Incumbent brand and DELISTED 1 May 2020

Temozolomide Orion Caps 5 mg 5 capsule bottle pack                         Pharmacode 2505940                                      Schedule price $10.20

Temozolomide Orion Caps 20 mg 5 capsule bottle pack                       Pharmacode 2505959                                      Schedule price $18.30

Temozolomide Orion Caps 100 mg 5 capsule bottle pack                    Pharmacode 2505967                                      Schedule price $40.20

Temozolomide Orion Caps 140 mg 5 capsule bottle pack                    Pharmacode 2527162                                      Schedule price $56.00

Temozolomide Orion Caps 250 mg 5 capsule bottle pack                    Pharmacode 2505975                                      Schedule price $96.80

Temizole Caps 20 mg 5 capsule bottle pack                                            Pharmacode 2527170                                        Schedule price $96.80

Reference pricing will not apply.

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 May 2020.

Brand Switch Fee not in notification.

As of the date of this notification ProPharma / PWR cannot accept Temozolomide Orion (all strengths) for credit under any circumstances.

From 1 December 2019 community pharmacies dispensing Temozolomide Capsules will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 May 2020. Failure to do so may prove costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both products listed and fully funded until the commencement of the sole supply 1 May 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change , however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close